A Randomized, Open Label, Multi Dose, Cross Over Design Clinical Study to Evaluate the Pharmacokinetic Pharmacodynamic Characteristics and Safety of AD-213-A and AD-2131 After Oral Administration in Healthy Adult Subjects
Latest Information Update: 28 Apr 2022
At a glance
- Drugs AD 213 (Primary)
- Indications Reflux oesophagitis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Addpharma
- 25 Apr 2022 Status changed from active, no longer recruiting to completed.
- 25 Nov 2021 Status changed from suspended to active, no longer recruiting.
- 20 Jul 2021 Planned End Date changed from 1 Aug 2021 to 1 Feb 2022.